Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dollars per share.
...I don't think it would be unreasonable for Anavex after all costs, expenses, taxes ,etc. to have a net income equal to 25% of that amount, or $20 billion.
Clinical results are required.
falconer, do you want to put together a 100 word blurb for release [for re-posting on other message boards, informing readers of how Anavex will change things]?
When the public learns....
It [AVXL share price] will certainly run up on great results (perhaps to $40), but will eventually be brought back down to $30. Hope I'm wrong, but history shows that $AVXL is being controlled.
Anavex 1066 binds to sigma-1 and -2 receptors
What is the MOA [mechanism of action] for 1066?
Pure brilliance, actually.
...let's assume for purposes of discussion that both 2-73 and 1066 will be megablockbuster drugs. How could you account for one tiny company coming up with two such pharmaceuticals? The odds against just one are unreal.
More game-changing Anavex science.
New Anavex patent, for analgesia (pain relief):
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210196708%22.PGNR.&OS=DN/20210196708&RS=DN/20210196708
I took the time to read slowly all of Missling’s new patent application. It patents the use of Anavex 1066 (“AV1066") to treat or prevent a diversity of pains.
I was particularly interested to see the evidence for efficacy. Using rather standard and accepted protocols to test for pain relief in lab rats, the new drug was administered in a diversity of dosage regimens for a plethora of pains specifically induced in the rats.
Results were statistically significant (p values of 0.05 or less). Results were not by chance; the induced pains were significantly reduced or eliminated. The stuff works.
I didn’t see any data telling of adverse events, side effects. Those will have to be assessed in human trials.
After some human trials of AV1066 showing both efficacy and safety, a new phrase might emerge: “If it hurts, take AV1066.”
Of course, there is a diversity of existing analgesics. But they are either only moderately effective, or have considerable, even obviating side effects.
Those competent in 8th-grade arithmetic can estimate the revenues this new Anavex analgesic would generate. Nine, ten, or eleven zeros after the integer.
Of course, as before, helpful individuals will caution everyone that mice (and rats) aren’t men; that drugs that test in murines don’t always work in real people. My dollars, however, will stay with my ownership of my AVXL shares. I see Anavex analgesia as another new, giant revenue-generator. Human trials first. Then....
Eventually....
...Anavex isn't getting the love on the AD front like those other two but that is a temporary situation and when it changes it will change in a big way.
Lesson not learned.
If you had bought just one share of Microsoft at the IPO, you would now have 288 shares after all the splits. Those shares would be worth $44,505 at the current stock quote of $154.53.
Well, then, tell the experiments.
These are experimental drugs....
Yes, the unappreciated veterinary scene.
I might suggest giving Anavex 2-73 to dogs that are 6 or 7 years of age.
Protein folding pathology in domestic animals
Blarcamesine naysayings becoming difficult.
Not only is 2-73 scoring 100 percent in its trials, but it also seems to be scoring 100 percent on every new relevant study that appears.
Rich, yes. But of what sort?
And we're all going to be filthy rich!!!
The game is changing.
Today’s share price ascent is strong and steep. New highs of the day in sequence. Sure, an afternoon retreat of some degree is likely. Nonetheless, the trading volume and direction (“momentum”?) are stronger than recent periods. AVXL is now playing in a new investment league.
That’s because the Anavex story, particularly with the outstanding new clinical data, is now solid. As mentioned, Anavex verbiage is no longer necessarily in the subjunctive, with phrases such as “might someday happen,” “but results need to be seen in real patients,” or “a young, untested startup.” Now, when conducting DD (determining diligence, due or undue) by consulting the Anavex website news page (https://www.anavex.com/news/) even to those unfamiliar with medical science the clinical results in the Parkinson’s disease dementia (PDD) study are understood to be profoundly positive. No ifs, ands, or buts.
There are now solid clinical data sets that validate the clinical significance of blarcamesine. Investors who have done their determining diligence can now clearly see the future of both Anavex Life Sciences Corp and its game-changing drug blarcamesine.
Decline of the subjunctive, expansion of the imperative.
Yes, blarcamesine is less frequently being referred to in the subjunctive mood. In grammar, the subjunctive sets out something as contingent on something else, or not yet certain.
Now, more than ever, blarcamesine is being referred to in the imperative, where there is certainty about what is being claimed.
Fewer ifs, ands, or buts. Now, “reveals,” “produces,” and “reduces” are the operating terms.
In time, it will be imperative for the FDA to approve the drug.
But probably only in utero.
The way I read the article, it seems to generally support 2-73 insofar as it is able to remediate chromatin problems in neurons.
Some thoughts beyond the horizon....
Now, this is way out; for cerebral consideration only; not to influence any AVXL buy or sell actions.
Ok, Anavex has filed for a European patent for its chemical, blarcamesine (Anavex 2-73), aimed at various neurodevelopmental diseases and conditions. The one that caught my attention was trisomy-21, Down's syndrome. I could make no sense as to how blarcamesine might resolve the many problems caused by the extra 21st chromosome in the condition.
Could this be the mechanism? Is the company focusing on favorable new prophylaxis during gametogenesis, when eggs and sperms are formed in the gonads (ovaries and testicles) of parents? Might the homeostatic processes induced or modulated by blarcamesine facilitate the autophagic destruction of aberrant gametes, thereby obviating any and all of the aneuploid diseases? Only good, genetically-sound gametes would be produced.
Might blarcamesine prevent the production of gametes with other genetic or biochemical defects? Only good ones would be produced, obviating otherwise consequent genetic diseases.
Now, of course, for this to happen, blarcamesine would have to be consumed during gametogenesis. Not so problematic for males, as sperm production occurs during reproductive years, adolescence through older age. But in females oogenesis, egg production, at least in the earliest stages, begins even before birth, before a future mother is even born.
Therefore, for blarcamesine to facilitate the production of genetically sound ova, it would have to be available in utero. Pregnant mothers would have to consume it.
If that promised the birth of genetically sound babies or grand children, think that mothers would then take the drug?
Formerly, I've proposed that blarcamesine is likely to be universally prescribed starting in patients' forth decade, to obviate the many diseases and conditions of aging. Now, there is the conjecture that humans will be dosed with blarcamesine, in utero, even before birth. What sorts of diseases and conditions might that prevent?
In ten years, will blarcamesine (or, perhaps more likely, Anavex 3-71) be administered to everyone, through all of the years of life, maintaining the health of youth and preventing the diseases of old age? I'm betting that Anavex has preliminary data on all of this, from murine (lab rodent) tests.
More undisclosed Anavex info.
From the European Patent Office: ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS
Because of the numbers, and legacy perceptions
...why would they bite on this, after their due diligence, if in your opinion its not particularly impressive...
Not a competitor.
Any comment regarding this development and the science behind it (vis-a-vis AVXL)
Anavex 2-73 modulation of bone health.
Do you think that 2-73 would have an effect on the body's ability to regenerate its bone growth?
Clinical metrics not yet relevant.
So how good was the PDD/PD data? It kind of suprised me that not that much has been discussed about the data. P- values , secondary endpoints, etc.
Wish I could, but....
Would you care to reveal the other 2 holdings?
We have the best messages and posters.
...so many great posters here.
We'll go for ten bucks.
I vote for ten bucks for a day's treatment resulting in $25.55 billion income seems acceptable to me.
Probably less than five years.
...a 100-bagger from here isn't so far afield, maybe within 5-10 years....
Projected Anavex Revenues.
I wanna see falconers (updated) spreadsheet that speculates on various revenues from the various indications that pertain to AVXL's pipeline....
Extremely significant perspectives.
...there is direct cross-talk between telomeres and autophagy....
And,
In surprising reversal, scientists find a cellular process that stops cancer before it starts....
Cellular recycling process, thought to fuel cancer's growth, can actually prevent it...
Apples and oranges; telomeres and sigma-1 receptors.
Senescence and telomeres, lab mice vs wild mice
Not applicable. Anavex is centered on SIGMAR1.
I'd love to hear your thoughts on this, particularly in regard to the research done on A2-73.
Well, Barchart is 100% positive.
How many up days in a row now, excluding the one down day after the offering?
First, check the history of the FDA.
My question is what is your honest opinion of the fda ?
Only one thing counts.
The FDA holds all the cards. Trial results are all that matters.
It's the sigma-1 activation work-around.
I don’t understand how agonising S1R along with modulating M1/M4 can counter cell dysfunction ever present curtesy of a gene mutation. It may not be well understood at present, just intrigued to find out what might be going on.
Far bigger.
Tip of the iceberg…
Nonetheless, no evidence of toxicity.
I disagree with your logic. Just because it takes a very small amount of 3-71 to agonize SR-1 doesn't mean that it has no other negative effects just because it takes a miniscule amount.
Safety of Anavex 3-71
For 3-71, The only news I want to hear is "It's SAFE".
More sigma-1 receptors? Or better activation?
...if someone takes Anavex 2-73, the result will be that the person gains more sigma-1 receptors, as well as having their sigma-1 receptors activated?
Accelerated Approval of Blarcamesine
...do you think that AVXL will apply for accelerated approval based upn the biomarker that they emphasized today?
Telling the Anavex story in the press.
...don’t you think the connection that PDD has to Parkinson’s disease itself, as well as to AD makes good PDD results better positioned to get lots of press??
Let me clarify the mRNA question.
ANAVEX®2-73 treatment resulted in increases in the mRNA expression of SIGMAR1....